Faulty brain satiety centers and impaired gut hormone function are risk factors for weight gain in T2 diabetes. A simple antidote? Slow down.
Is Metformin Still Top Drug for Type 2 Diabetes?
A new study evaluated the comparative effectiveness and safety of monotherapy and selected metformin-based combinations for type 2 diabetes.
How Much Does GLP-1 RA Impact Glucose, Weight?
Clinical trials have shown that GLP-1 RAs reduce HbA1c and weight in type 2 diabetes, but are these outcomes confounded by concomitant medications?
Risk of Cardiovascular Events with Dulaglutide
A meta-analysis examined the effect of treatment with a GLP-1 receptor agonist on cardiovascular event risk in type 2 diabetes patients.
GLP-1 RA Effectiveness in Asian vs White Patients
Unlike typical Western patients, type 2 diabetes patients in Asia tend to have lower BMIs. Does this mean responses to GLP-1 RAs differ as well?
Comparing Weight Loss with Liraglutide
Does a GLP-1 receptor agonist offer the same weight-loss benefits to different racial subgroups?
Weight Loss Drug Therapy in Type 2 Diabetes
Which GLP-1 receptor agonist induced weight loss in type 2 diabetes patients?
GLP-1 Agonist Pop Quiz
Take a short break from the clinic and try 2 quick questions about the injectable gut hormone analogs.
QW GLP-1 RAs: Impact on A1c and Weight
All 3 once-weekly GLP-1 RAs effectively reduce A1c and promote weight loss. Similarities and important differences are parsed in these slides.
What Impact of Weight on GLP-1-stimulated Insulin Secretion?
The size of the incretin effect among healthy subjects may vary up to 2-fold, suggesting differences in ß-cell sensitivity to GLP-1. Does BMI play a role in this variability?
Albiglutide Effective in Triple Therapy for Uncontrolled Type 2 Diabetes
In obese patients with type 2 diabetes uncontrolled by lifestyle and two oral agents, albiglutide significantly lowered A1c as part of 3-drug therapy.
GLP-1 Receptor Agonists and Cardiovascular Outcomes: 3 Studies
Cardiovascular disease is the underlying cause of death in more than 60% of patients with T2DM. GLP-1 receptor agonists have shown promising cardioprotective effects.
By clicking Accept, you agree to become a member of the UBM Medica Community.